Dexcom Inc Stock Price, News & Analysis

Dexcom announces the launch of its G7 Continuous Glucose Monitoring (CGM) System in the UK, Ireland, Germany, Austria, and Hong Kong, aimed at people aged two and older. The G7 features the fastest sensor warmup in the market, with no finger sticks required, and builds on the accuracy of Dexcom's previous products. A global streaming launch event showcased the device, with plans for launches in New Zealand and South Africa soon. With improved design and integration into automated insulin delivery systems, Dexcom G7 marks a significant advancement in diabetes management.

DexCom, Inc. (NASDAQ:DXCM) will release its third quarter 2022 financial results on October 27, 2022, after market close.

A conference call is scheduled for 4:30 p.m. (Eastern Time) on the same day to review performance, with a webcast available on their investor relations website.

Investors can call in at (866) 374-5140 (US/Canada) or (404) 400-0571 (International) using confirmation number 56107665#.

DexCom, Inc. (NASDAQ:DXCM) announced that Jereme Sylvain, Executive Vice President and CFO, will present updates at upcoming investor conferences. The events include the Wells Fargo 2022 Healthcare Conference on September 7, 2022, at 2:35 PM (EST), and the Baird 2022 Global Healthcare Conference on September 14, 2022, at 8:30 AM (EST). Webcasts for these presentations will be available on the DexCom Investor Relations website, offering future access to the discussions.

DexCom, Inc. (NASDAQ: DXCM) has announced the promotion of Jake Leach to chief operating officer. Previously serving as chief technology officer, Leach has been instrumental in developing the company's continuous glucose monitoring (CGM) systems since 2004. The new role will see him take charge of product management and oversee operations, R&D, and quality control, reinforcing DexCom's commitment to innovation in diabetes technology. His expanded leadership aims to position DexCom for sustainable growth in providing CGM solutions to a wider audience.

DexCom, Inc. (NASDAQ:DXCM) announces that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 10:30 AM (EST). The presentation aims to provide an update on the company's ongoing efforts in diabetes care technology. Interested parties can access the webcast through the Dexcom Investor Relations website, where it will also be archived for future viewing.

The Dexcom ONE rt-CGM system has been officially listed on the NHS drug tariff in England, Wales, Scotland, and Northern Ireland, making it the first scan-free and finger prick-free device available for prescription for individuals with Type 1 and Type 2 diabetes who use insulin. This significant milestone, effective from August 1, enables easier access to advanced diabetes management technology. Dexcom aims to enhance patient outcomes and provide more choices in diabetes care through this initiative, in line with NICE's new guidelines on glucose sensors.

DexCom reported a 17% increase in Q2 2022 revenue, reaching $696.2 million, driven by strong customer growth and international expansion.

U.S. revenue grew 11%, while international revenue surged 39%. GAAP operating income fell to $77.0 million, down 590 basis points year-over-year, with a decline in non-GAAP operating income to $101.9 million.

Net income decreased to $50.9 million or $0.12 per diluted share. The company updated its fiscal 2022 guidance, projecting revenue between $2.86 billion and $2.91 billion, reflecting a growth rate of 17-19%.

Dexcom (NASDAQ: DXCM) enhances user experience by launching its G6 mobile app in Spanish, facilitating easier access for Spanish-speaking diabetes patients. This feature addresses language barriers that impact healthcare quality. As reported, diabetes affects 11.8% of U.S. Latino adults, with a significant risk for complications. The updated app is available on compatible iOS and Android devices, contributing to health equity and improved diabetes management. The company aims to empower users with real-time glucose monitoring, fostering better health decisions.

Dexcom, Inc. (NASDAQ:DXCM) has been certified as a Great Place to Work® in Canada for 2022-23, awarded by Great Place to Work Institute®. This recognition is based on employee feedback, with 92% expressing pride in their workplace. Senior Vice President Laura Endres emphasized the importance of their dedicated workforce in achieving this honor. The company is focused on enhancing employee experience and expanding its presence in Canada, aiming to improve diabetes management technology for Canadians.